Smoking cessation and glycaemic control in type 2 diabetic patients

Iino, Kozo; Iwase, Masanori; Tsutsu, Nobutaka; Iida, Minoru

doi:10.1111/j.1462-8902.2004.00329.x

Cited by 46 publications

(21 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, Solberg et al [13] observed that the subjects with DM who smoke are less active in the care of their DM and are less interested in stopping smoking than smokers without DM. Some authors argue that subjects with DM who smoke are resistant to the idea of giving up smoking because of the fear that they will either gain weight or develop a related lack of appetite control and, later, a worsening of the metabolic control because tobacco helps them to control their weight [6,19,20]. Other authors comment that these patients, unlike other groups, feel that they are already so restricted by the need to maintain appropriate metabolic levels that they are unwilling to relinquish their smoking habit as well and do not see themselves as vulnerable or at risk of death [11,21].…”

Section: Discussionmentioning

confidence: 99%

Results of the application of the American Diabetes Association guidelines regarding tobacco dependency in subjects with diabetes mellitus

et al. 2009

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Results of the application of the American Diabetes Association guidelines regarding tobacco dependency in subjects with diabetes mellitus

et al. 2009

View full text Add to dashboard Cite

“…The datasheets for most recommended first-line smoking cessation medications31 caution against their use in diabetes 832 Moreover, studies report that smoking cessation may worsen metabolic profile and glycaemic control33 34 and lead to weight gain 35. We have identified four trials not included in the narrative review, two predating the narrative review 17…”

Section: Discussionmentioning

confidence: 99%

Smoking cessation in adults with diabetes: a systematic review and meta-analysis of data from randomised controlled trials

et al. 2014

View full text Add to dashboard Cite

ObjectivesTo evaluate the effects of more intensive smoking cessation interventions compared to less intensive interventions on smoking cessation in people with type 1 or type 2 diabetes.DesignA systematic review and meta-analysis of randomised trials of smoking cessation interventions was conducted. Electronic searches were carried out on the following databases: MEDLINE, EMBASE, CINAHL and PsycINFO to September 2013. Searches were supplemented by review of trial registries and references from identified trials. Citations and full-text articles were screened by two reviewers. A random-effect Mantel-Haenszel model was used to pool data.SettingPrimary, secondary and tertiary care.ParticipantsAdults with type 1 or type 2 diabetes.InterventionsSmoking cessation interventions or medication (more intensive interventions) compared to usual care, counselling or optional medication (less intensive interventions).Outcome measuresBiochemically verified smoking cessation was the primary outcome. Secondary outcomes were adverse events and effects on glycaemic control. We also carried out a pooled analysis of self-reported smoking cessation outcomes.ResultsWe screened 1783 citations and reviewed seven articles reporting eight trials in 872 participants. All trials were of 6 months duration. Three trials included pharmacotherapy for smoking cessation. The risk ratio of biochemically verified smoking cessation was 1.32 (95% CI 0.23 to 7.43) for the more intensive interventions compared to less intensive interventions with significant heterogeneity (I2=76%). Only one trial reported measures of glycaemic control.ConclusionsThere is an absence of evidence of efficacy for more intensive smoking cessation interventions in people with diabetes. The more intensive strategies tested in trials to date include interventions used in the general population, adding in diabetes-specific education about increased risk. Future research should focus on multicomponent smoking cessation interventions carried out over a period of at least 1 year, and also assess impact on glycaemic control.

show abstract

“…Smoking is associated with insulin resistance [17], dyslipidaemia [18] and an increased propensity for type 2 diabetes [19, 20] through a body mass index-independent mechanism [21]. Contrary to what one might expect, stopping smoking does not reduce these metabolic abnormalities but, by mechanisms not well understood, is often accompanied by increased weight and a further increase in the risk of diabetes [22, 23]. …”

Section: Schizophrenia As An Independent Risk Factor For Metabolic Symentioning

confidence: 99%

Antipsychotic-Induced Metabolic and Cardiovascular Side Effects in Schizophrenia: A Novel Mechanistic Hypothesis

Scigliano

Ronchetti

2013

CNS Drugs

View full text Add to dashboard Cite

The use of antipsychotics is hindered by the frequent occurrence of metabolic and cardiovascular side effects, resulting in worsened quality of life and greater mortality as a result of cardiovascular and cerebrovascular disorders in schizophrenia patients than the comparable general population. The various antipsychotics induce extrapyramidal symptoms, impaired glucose and lipid metabolism, weight gain, hypertension and arrhythmias, with variable frequency. Second-generation antipsychotics appear to have several advantages over first-generation antipsychotics, including a claimed better action on cognitive function and the negative symptoms of schizophrenia, and lower frequency of extrapyramidal side effects; however, their use is associated with a greater frequency of metabolic and cardiovascular disturbances. The mechanisms of these important side effects are not well understood, and generic approaches (psychoeducational programmes and symptomatic therapies) have been proposed to limit their severity. Extensive data from the literature indicate that autonomic nervous system dysfunction—intrinsic to schizophrenia and strongly exacerbated by antipsychotic treatment—is the cause of the pervasive metabolic and vascular dysfunctions associated with schizophrenia. In this article, we marshal further literature data to argue that the metabolic and cardiovascular side effects of antipsychotics are primarily mediated by their ability to block peripheral dopamine receptors, which physiologically modulate sympathetic activity. We also propose that these effects might be overcome by providing peripheral dopaminergic stimulation.

show abstract

Smoking cessation and glycaemic control in type 2 diabetic patients

Abstract: Glycaemic control and diastolic blood pressure deteriorated in type 2 diabetic patients after quitting smoking. Type 2 diabetic patients who want to stop smoking need a caution to prevent deterioration of glycaemic control and blood pressure after quitting smoking.

Cited by 46 publications

References 30 publications

Results of the application of the American Diabetes Association guidelines regarding tobacco dependency in subjects with diabetes mellitus

Results of the application of the American Diabetes Association guidelines regarding tobacco dependency in subjects with diabetes mellitus

Smoking cessation in adults with diabetes: a systematic review and meta-analysis of data from randomised controlled trials

Antipsychotic-Induced Metabolic and Cardiovascular Side Effects in Schizophrenia: A Novel Mechanistic Hypothesis

Contact Info

Product

Resources

About